UPDATES ON HIV CURE RESEARCH final.pptx

Mainly for adolscents support in Africa.

1. UPDATES ON HIV CURE RESEARCH BY MR. CRISTUS ATUKWASE

2. SELECTED RESEARCH AT JCRC RESEARCH THAT MAY IMPACT OUR LIVES JCRC Bulletin-2021 About us: " Since its inception spanning 30 years to date, the Centre has been part of landmark studies that have informed policy and best practices in HIV prevention and treatment . 2 HOW? Through Antiretroviral Therapy Simplification for children and Adults

3. ART Simplification Strategy: WHAT ‘s THE RATIONALE ? Bridging gaps/Challenges of HIV treatment like : Maximise the benefit of ART/Minimise long-term toxicity Maintain long-term adherence to prevent resistance and maximise future drug options Enable wider roll-out of ARVs limitations such as in dosing , formulation and acceptability 3

4. ODYSSEY TRIAL WHAT IS NEW AND WHAT HAS EMERGED IN THIS TRIAL TO ATTRACT OUR ATTENTION ? It has directly influenced policy and practice nationally and internationally. As an example, the ODYSSEY trial was recently published in the New England Journal of Medicine (December 2021) which showed that Dolutegravir -based regimens could be safely used in children and adolescents and were effective as first-line or second line therapy. This is a landmark trial in the optimization of treatment options for children and adolescents infected with HIV . 4

5. BREATHER- PLUS TRIAL WHAT IS IT ALL ABOUT ? In addition to what is listed above about bridging gaps of HIV treatment, breather plus focuses on: Challenges of treating young people for example: Lifelong therapy Adherence rates fall in adolescence, related to medication (taste/ palatability) and social dimensions (e.g. staying with friends at weekends) 5

6. BREATHER- PLUS TRIAL WHY IS IT IMPRESSIVE ? AND HOW ? It’s a possible answer to the Need for new treatment strategies. What’s the Possible strategy: Short Cycle Therapy (SCT): 5 days on treatment with weekends off, compared with Continuous Therapy (CT). Simplification with less toxicity Better adherence Cost savings 6

7. CARES STUDY WHAT IS IT ABOUT ? Answer is : It’s the new Long-Acting Injectable ART . Background info: (why is it important?) Over time, improvements have been made in the treatment of HIV to enhance adherence, decrease pill burden, decrease short and long term side effects, increase barriers to developing resistance and decrease dosing frequency. 7

8. CARES STUDY WHAT IS IT ABOUT ? Cont’d. Background info: (why is it important?) Further simplification has led to the development of long-acting depot injections, the first of which was recently approved/licensed by the Food and Drug Administration (FDA) in January 2021. 8

9. CARES STUDY This study, therefore, sets out to answer these questions among others. Can the public health system adopt less frequent monitoring especially for viral loads that are required to see if the medicine is still working ? Will this treatment work where there is a possibility of background resistance to ART ? Will the participants be able to return on time for their treatment ? What is the preference for the African population? 9

10. Next Frontiers of Science The Centre will build on the foundations of 2021 to extend work into the new year 2022 2022. The work will include among others Long-Acting ART for HIV prevention Preliminary research in preparations for Gene Therapy for HIV and SCD Cure What is my Key Focus? Global Gene Therapy Initiative (GGTI )-Gene Therapy for HIV and Sickle Cell Disease CURE WATCH THE VIDEO 10

11. ARE YOU HAPPY NOW? Does this give you hope? ,Is the future bright? Can you hold on further once more? Is this another chance to organize yourself and achieve your dreams? 11

12. Where do you see yourself in the next five Years? 12 Large image

13. Thank You CRISTUS ATUKWASE + 256788982450 m [email protected] WWW.JCRC.ORG.UG 13